Limiting post-transplantation kidney loss

Limiting post-transplantation kidney loss

Immunosuppression following kidney transplantation leads to an increase in BK virus activity, causing kidney damage and loss. A novel RNA-targeting therapy has been developed that homes to the kidney, and inhibits BK virus activity. Among others, in this project a novel in vivo BK virus-inhibiting model has been developed to screen and optimize antisense oligonucleotide candidates. The LUMC spin-out company Hybridize Pharma has been founded to advance the development of this highly promising therapy.

Learn more about Hybridiza Pharma and its new therapy against kidney loss due to BK-virus infection.

A Starfish Innovations project